(CNN) — The U. S. Food and Drug Administration has been in the U. S. Food and Drug Administration. The U. S. Food and Drug Administration on Wednesday legalized the use of Novavax’s COVID-19 vaccine as a first booster dose in adults 18 and older, at least six months after completing an initial COVID-19 vaccine.
The Gaithersburg, Maryland-based company announced that it has obtained emergency use authorization to provide a first booster dose of its vaccine to adults for whom an updated booster vaccine approved by the FDA from Pfizer/BioNTech or Moderna cannot be obtained or is not clinically appropriate. , and adults who choose to receive the Novavax vaccine because they would not otherwise get a booster dose of a Covid-19 vaccine.
Previously, the Novavax vaccine was only used as a component of a number one two-dose vaccine. This is the fourth coronavirus vaccine in the United States. Unlike the others, it uses protein-based technology.
“The United States now has the Novavax COVID-19 vaccine, with adjuvant, the first protein-based option, as a booster,” Novavax Chairman and CEO Stanley Erck said Wednesday in a press release. “According to CDC data, only about 50 percent of adults who have won their number one series have not yet gained their first booster dose. Offering a selection of exchange vaccines can help increase COVID-19 booster vaccination rates for those adults. “
In July, the FDA legalized Novavax’s Covid-19 vaccine for use in a number one two-dose series in adults, and the authorization was extended in August for teens ages 12 to 17.
Novavax executives have long advised that their covid-19 vaccine can only be used as a booster dose, even for other people who have won some sort of vaccine like the main series.
Protein-based vaccines use a more classic technique than mRNA vaccines like Pfizer’s and Moderna’s Covid-19 vaccines, training the immune formula to recognize small altered parts of the virus targeted by the vaccine. In this case, these are fragments of the coronavirus. The vaccine created from a genetic series of the original strain of the coronavirus. This generation is also used for vaccines against diseases such as hepatitis B and whooping cough.
As of Monday, about two-thirds of the U. S. population is in the U. S. population. The U. S. population (68%) are fully vaccinated with at least their initial COVID-19 vaccine series. But about a third (33. 5%) of the population gained a booster dose of the vaccine.
El-CNN-Wire™